FDA Licenses Simulations Plus’s GastroPlus Software
Simulations Plus said this week that the US Food and Drug Administration has licensed its GastroPlus simulation software for use in its internal research.
Walt Woltosz, chairman and CEO of Simulations Plus, said in a statement that the company recently worked on “a few projects” with FDA scientists using GastroPlus that resulted in joint publication of scientific posters.
Woltosz said that the FDA is “advocating for better simulation and modeling tools,” citing as evidence the agency’s Critical Path whitepaper, which listed “computer-based predictive models” among a number of technologies that are “urgently needed” to speed the drug approval process.
Financial terms of the agreement were not provided.
HUPO’s PSI Seeks Comment on Proteomics Standards Manuscripts
The Human Proteome Organization’s Proteomics Standards Initiative is seeking comments on several manuscripts that are under consideration for publication in Nature Biotechnology.
Four manuscripts from the HUPO PSI and three more manuscripts with participation from PSI are posted on Nature Biotech’s community consultation page for public comment.
There are currently nine papers available on the community consultation page, covering a range of proposed standards. These include MIGS (Minimum Information about a Genome Sequence), MIAPE (Minimum Information About a Proteomics Experiment), PSI-MOD (a standard for representing protein modification data), MIAPE: Mass spectrometry, MIAPE: Mass spectrometry informatics, MIAPE: Gel Electrophoresis, FuGE (The Functional Genomics Experiment model), MISFISHIE (Minimum Information Specification For In Situ Hybridization and Immunohistochemistry), and MIMIx (Minimum Information required for reporting a Molecular Interaction Experiment).
Clarabridge Joins BioIT Alliance
Text-mining software provide Clarabridge said that it has joined the Microsoft-led BioIT Alliance.
Clarabridge markets the Content Mining Platform, which de-identifies patient data and integrates with terminology standards such as SNOMED.
Tripos Faces Delisting From Nasdaq for Low Share Price, Market Cap
Tripos said this week that it is in jeopardy of being delisted from the Nasdaq exchange for not maintaining the minimum market cap and minimum share bid price for 30 consecutive days.
The company said it has 90 days to regain market-cap compliance and 180 days to regain share-price compliance.
To regain compliance the company must have more than $5 million in publicly traded outstanding shares, not including those held by directors or corporate officers, for at least 10 consecutive days before April 4.
In order to regain share-price requirements, the company’s stock price must close at $1 per share or more for a minimum of 10 consecutive business days before July 3.
Tripos said it is “evaluating its alternatives” to resolve the matter. If it is unable to do so the company said it may transfer its common stock to the Nasdaq Capital Market, at which point Nasdaq would stop the proceedings to delist the company.
The company is in the process of selling its Discovery Informatics and Discovery Research businesses to two different buyers. In November it said it would sell its Discovery Informatics business to Vector Capital in the first quarter of this year [BioInform 11-27-07]. Last week, it said it would sell its Discovery Research business to Provid Pharmaceuticals [BioInform 01-05-07].
OmniViz, ChemAxon to Integrate Software
Visualization software firm OmniViz and cheminformatics provider ChemAxon said this week that they are integrating ChemAxon’s Marvin chemical visualization suite within OmniViz’ Titanium data visualization and analysis product.
OmniViz will integrate the latest MarvinView 4.1.4 release into the next version of its software the companies said.
The new version of MarvinView will enable Titanium users to work with more structure and image file formats, including the InChI file format.
The collaboration extends an earlier integration agreement between the companies.